EP Patent

EP3833762A4 — OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES

Assigned to Verseau Therapeutics Inc · Expires 2022-09-28 · 4y expired

What this patent protects

Patent listed against Onpattro.

Drugs covered by this patent

Patent Metadata

Patent number
EP3833762A4
Jurisdiction
EP
Classification
—
Expires
2022-09-28
Drug substance claim
No
Drug product claim
No
Assignee
Verseau Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.